SAN DIEGO, CA USA (UroToday.com) - Given the relative equivalency using available data and lack of quality, high-level trials, many have focused on quality of outcomes to compare localized prostate cancer therapies.
However, data remains sparse regarding late declines in health-related quality of life and long-term quality-of-life outcomes after primary treatment of localized prostate cancer. The authors of this study assess long term quality of life in men with prostate cancer using a longitudinal, nationwide, prostate cancer registry.
The CaPSURE database has prospectively and longitudinally collected clinical and quality of life data in men with prostate cancer since 1995. Encompassing 3 777 men who underwent radical prostatectomy (60%), brachytherapy (20%), external beam radiotherapy (12%), primary androgen deprivation therapy (6%), and active surveillance or watchful waiting (2%), quality of life was assessed using well-validated, self-reported questionnaires. The median follow up was 52 months. Quality of life was seen to decline in the first 2 years post-treatment and then to plateau. Although radical prostatectomy was slightly worse for urinary symptoms than other treatments, these differences were small and radical prostatectomy appeared to fare slightly better for bowel and mental health. Following the initial plateau, quality-of-life changes vary little from 3 to 10 years post-treatment, a trend that appeared consistent over the various modalities.
These data can help clinicians to manage patient expectations over time and in various quality-of-life domains, post-treatment.
This poster received an award for the best in session.
Presented by Sanoj Punnen, Janet Cowan, Peter Carroll, and Matthew Cooperberg at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA
Reported for UroToday.com by Anthony T. Corcoran, MD
